Rhenman & Partners Asset Management AB Purchases 107428 Shares of Xencor Inc (XNCR)

AQR Capital Management LLC raised its holdings in shares of Xencor by 105.6% during the third quarter. AQR Capital Management LLC now owns …

Xencor logoRhenman & Partners Asset Management AB increased its position in shares of Xencor Inc (NASDAQ:XNCR) by 49.2% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 325,965 shares of the biopharmaceutical company’s stock after acquiring an additional 107,428 shares during the period. Rhenman & Partners Asset Management AB owned about 0.58% of Xencor worth $10,124,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently made changes to their positions in the company. JPMorgan Chase & Co. raised its holdings in shares of Xencor by 5.2% during the third quarter. JPMorgan Chase & Co. now owns 251,155 shares of the biopharmaceutical company’s stock worth $9,787,000 after acquiring an additional 12,320 shares in the last quarter. Tower Research Capital LLC TRC purchased a new stake in shares of Xencor during the third quarter worth $142,000. Tekla Capital Management LLC purchased a new stake in shares of Xencor during the fourth quarter worth $2,031,000. AQR Capital Management LLC raised its holdings in shares of Xencor by 105.6% during the third quarter. AQR Capital Management LLC now owns 63,061 shares of the biopharmaceutical company’s stock worth $2,457,000 after acquiring an additional 32,389 shares in the last quarter. Finally, 361 Capital LLC purchased a new stake in shares of Xencor during the fourth quarter worth $2,596,000. Institutional investors and hedge funds own 84.71% of the company’s stock.

NASDAQ XNCR opened at $31.62 on Thursday. Xencor Inc has a fifty-two week low of $27.57 and a fifty-two week high of $48.38. The stock has a market cap of $1.78 billion, a price-to-earnings ratio of -24.14 and a beta of 1.40.

Several analysts recently issued reports on XNCR shares. Raymond James initiated coverage on Xencor in a report on Thursday, March 14th. They set an “outperform” rating and a $27.85 price objective for the company. BidaskClub upgraded Xencor from a “hold” rating to a “buy” rating in a report on Tuesday, January 1st. Piper Jaffray Companies raised their target price on Xencor to $56.00 and gave the company an “overweight” rating in a report on Tuesday, February 26th. Cantor Fitzgerald restated a “buy” rating and set a $40.00 target price on shares of Xencor in a report on Tuesday, February 5th. Finally, ValuEngine lowered Xencor from a “strong-buy” rating to a “buy” rating in a report on Thursday, February 28th. Two research analysts have rated the stock with a sell rating and nine have given a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $41.43.

In related news, major shareholder John S. Stafford III bought 2,000 shares of the business’s stock in a transaction on Friday, March 22nd. The shares were bought at an average cost of $29.96 per share, for a total transaction of $59,920.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, major shareholder John S. Stafford III bought 1,100 shares of the business’s stock in a transaction on Monday, March 18th. The shares were bought at an average price of $29.90 per share, for a total transaction of $32,890.00. The disclosure for this purchase can be found here. Over the last 90 days, insiders have acquired 46,900 shares of company stock worth $1,368,396. Corporate insiders own 4.70% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was originally reported by Fairfield Current and is owned by of Fairfield Current. If you are reading this news story on another website, it was stolen and reposted in violation of international copyright laws. The correct version of this news story can be read at https://www.fairfieldcurrent.com/news/2019/04/11/rhenman-partners-asset-management-ab-purchases-107428-shares-of-xencor-inc-xncr.html.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions.

Featured Article: What is a Lock-Up Period?

Want to see what other hedge funds are holding XNCR?Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xencor Inc (NASDAQ:XNCR).

Institutional Ownership by Quarter for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Xencor and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Is Great Panther Mining Limited (GPL) A Stock To Be Permanently Long On?

Similar statistics are true for the second largest owner, Renaissance Technologies Llc, which owns 3,309,049 shares of the stock are valued at $3.16 …

Great Panther Mining Limited (NYSE:GPL) is on recovery track with 71.66% gain from a 1-year low price of $0.54. The company lost -3.71% to attain the price of $0.92 on 4/10/2019. Throughout the recent session, the prices were hovering between $0.9101 and $0.98. These shares are 131.52% off its target price of $2.13 and the current market capitalization stands at $249.02M. The recent change has given its price a 0.96% lead over SMA 50 and -30.42% deficit over its 52-week high. The stock witnessed -15.74% declines, 29.35% gains and 10.65% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found GPL’s volatility during a week at 5.77% and during a month it has been found around 6.69%.

Great Panther Mining Limited (GPL) Top Holders

Institutional investors currently hold around $24 million or 15.1% in GPL stock. Look at its top three institutional owners: Van Eck Associates Corp owns $11.47 million in Great Panther Mining Limited, which represents roughly 4.61% of the company’s market cap and approximately 47.8% of the institutional ownership. Similar statistics are true for the second largest owner, Renaissance Technologies Llc, which owns 3,309,049 shares of the stock are valued at $3.16 million. The third largest holder is Financial & Investment Management Group Ltd, which currently holds $3.05 million worth of this stock and that ownership represents nearly 1.23% of its market capitalization.

Great Panther Mining Limited 13F Filings

At the end of December reporting period, 24 institutional holders increased their position in Great Panther Mining Limited (NYSE:GPL) by some 2,079,002 shares, 12 decreased positions by 4,600,006 and 6 held positions by 18,301,655. That puts total institutional holdings at 24,980,663 shares, according to SEC filings. The stock grabbed 12 new institutional investments totaling 615,588 shares while 5 institutional investors sold out their entire positions totaling 159,424 shares.

Great Panther Mining Limited (GPL) Analyst Guide

Not many analysts have released their opinion on Great Panther Mining Limited (NYSE:GPL), with 0 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 1 buy, 0 sell and 0 strong sell ratings, collectively assigning a 2 average brokerage recommendation [T1].

Related Posts:

  • No Related Posts

Millennium Management LLC Buys 428399 Shares of Fate Therapeutics Inc (FATE)

Millennium Management LLC boosted its stake in shares of Fate Therapeutics Inc (NASDAQ:FATE) by 269.0% during the 4th quarter, according to its …

Fate Therapeutics logoMillennium Management LLC boosted its stake in shares of Fate Therapeutics Inc (NASDAQ:FATE) by 269.0% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 587,640 shares of the biopharmaceutical company’s stock after buying an additional 428,399 shares during the period. Millennium Management LLC owned approximately 0.91% of Fate Therapeutics worth $7,539,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in FATE. Wells Fargo & Company MN grew its stake in Fate Therapeutics by 61.2% during the third quarter. Wells Fargo & Company MN now owns 189,563 shares of the biopharmaceutical company’s stock worth $3,088,000 after buying an additional 71,940 shares during the last quarter. Alliancebernstein L.P. grew its stake in Fate Therapeutics by 54.3% during the third quarter. Alliancebernstein L.P. now owns 42,600 shares of the biopharmaceutical company’s stock worth $694,000 after buying an additional 15,000 shares during the last quarter. BlackRock Inc. grew its stake in Fate Therapeutics by 5.6% during the third quarter. BlackRock Inc. now owns 3,469,531 shares of the biopharmaceutical company’s stock worth $56,519,000 after buying an additional 183,701 shares during the last quarter. Allianz Asset Management GmbH bought a new stake in Fate Therapeutics during the third quarter worth about $1,761,000. Finally, Renaissance Technologies LLC grew its stake in Fate Therapeutics by 137.2% during the third quarter. Renaissance Technologies LLC now owns 95,100 shares of the biopharmaceutical company’s stock worth $1,549,000 after buying an additional 55,000 shares during the last quarter. Institutional investors own 91.71% of the company’s stock.

In other news, Director Amir Nashat sold 39,483 shares of the stock in a transaction that occurred on Friday, January 18th. The shares were sold at an average price of $16.28, for a total transaction of $642,783.24. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider J Scott Wolchko sold 20,000 shares of the stock in a transaction that occurred on Thursday, March 21st. The shares were sold at an average price of $17.61, for a total transaction of $352,200.00. The disclosure for this sale can be found here. Insiders have sold 335,000 shares of company stock worth $5,000,154 over the last three months. 23.19% of the stock is owned by insiders.

FATE opened at $17.27 on Thursday. Fate Therapeutics Inc has a one year low of $8.35 and a one year high of $19.11. The company has a current ratio of 7.53, a quick ratio of 7.53 and a debt-to-equity ratio of 0.08. The company has a market cap of $1.12 billion, a PE ratio of -14.51 and a beta of 2.05.

Fate Therapeutics (NASDAQ:FATE) last released its quarterly earnings results on Tuesday, March 5th. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.24) by ($0.01). Fate Therapeutics had a negative net margin of 1,405.06% and a negative return on equity of 59.04%. As a group, equities analysts anticipate that Fate Therapeutics Inc will post -1.05 EPS for the current fiscal year.

Several brokerages have weighed in on FATE. Svb Leerink began coverage on shares of Fate Therapeutics in a research note on Thursday, March 28th. They set an “outperform” rating and a $20.00 price objective on the stock. Leerink Swann began coverage on shares of Fate Therapeutics in a research note on Thursday, March 28th. They set an “outperform” rating and a $20.00 price objective on the stock. Wells Fargo & Co upped their price objective on shares of Fate Therapeutics from $18.00 to $24.00 and gave the stock an “outperform” rating in a research note on Wednesday, March 6th. BidaskClub raised shares of Fate Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, March 5th. Finally, Zacks Investment Research raised shares of Fate Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, February 13th. Three equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $19.63.

WARNING: This article was originally published by Fairfield Current and is owned by of Fairfield Current. If you are reading this article on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.fairfieldcurrent.com/news/2019/04/11/millennium-management-llc-buys-428399-shares-of-fate-therapeutics-inc-fate.html.

Fate Therapeutics Company Profile

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its immuno-oncology product candidates include FATE-NK100, a natural killer (NK) cell cancer immunotherapy comprising adaptive memory NK cells; FT500, an induced pluripotent stem cell (iPSC)-derived NK cell product candidate for the treatment of advanced solid tumors; FT516, an iPSC-derived non-cleavable CD16 engineered NK cell product candidate to treat hematologic malignancies and solid tumors; and FT596, a chimeric antigen receptor (CAR) T-cell therapy for patients with hematologic malignancies.

Featured Article: Why is the LIBOR significant?

Want to see what other hedge funds are holding FATE?Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Fate Therapeutics Inc (NASDAQ:FATE).

Institutional Ownership by Quarter for Fate Therapeutics (NASDAQ:FATE)

Receive News & Ratings for Fate Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Fate Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Millennium Management LLC Invests $15.69 Million in GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Millennium Management LLC acquired a new stake in GW Pharmaceuticals PLC- (NASDAQ:GWPH) in the fourth quarter, according to the company in …

GW Pharmaceuticals PLC- logoMillennium Management LLC acquired a new stake in GW Pharmaceuticals PLC- (NASDAQ:GWPH) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 161,058 shares of the biopharmaceutical company’s stock, valued at approximately $15,685,000. Millennium Management LLC owned approximately 0.53% of GW Pharmaceuticals PLC- as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Horrell Capital Management Inc. grew its position in shares of GW Pharmaceuticals PLC- by 33.3% in the fourth quarter. Horrell Capital Management Inc. now owns 400 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 100 shares during the period. Edmond DE Rothschild Holding S.A. boosted its position in GW Pharmaceuticals PLC- by 16.7% during the fourth quarter. Edmond DE Rothschild Holding S.A. now owns 700 shares of the biopharmaceutical company’s stock worth $68,000 after acquiring an additional 100 shares during the last quarter. Resources Investment Advisors Inc. boosted its position in GW Pharmaceuticals PLC- by 51.9% during the fourth quarter. Resources Investment Advisors Inc. now owns 366 shares of the biopharmaceutical company’s stock worth $36,000 after acquiring an additional 125 shares during the last quarter. North Star Investment Management Corp. boosted its position in GW Pharmaceuticals PLC- by 48.2% during the fourth quarter. North Star Investment Management Corp. now owns 615 shares of the biopharmaceutical company’s stock worth $60,000 after acquiring an additional 200 shares during the last quarter. Finally, Sequoia Wealth Management LLC boosted its position in GW Pharmaceuticals PLC- by 11.4% during the third quarter. Sequoia Wealth Management LLC now owns 2,450 shares of the biopharmaceutical company’s stock worth $423,000 after acquiring an additional 250 shares during the last quarter. 79.42% of the stock is owned by institutional investors.

GWPH opened at $172.32 on Thursday. The company has a market capitalization of $5.09 billion, a P/E ratio of -16.32 and a beta of 2.80. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.34 and a current ratio of 6.66. GW Pharmaceuticals PLC- has a 1 year low of $90.14 and a 1 year high of $182.23.

A number of equities research analysts have recently issued reports on the stock. ValuEngine downgraded shares of GW Pharmaceuticals PLC- from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, January 2nd. Guggenheim started coverage on shares of GW Pharmaceuticals PLC- in a research note on Friday, February 22nd. They set a “buy” rating and a $178.00 target price on the stock. BidaskClub downgraded shares of GW Pharmaceuticals PLC- from a “buy” rating to a “hold” rating in a research note on Friday, February 8th. Zacks Investment Research raised shares of GW Pharmaceuticals PLC- from a “hold” rating to a “strong-buy” rating and set a $198.00 target price on the stock in a research note on Saturday, March 2nd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $196.00 target price (up from $193.00) on shares of GW Pharmaceuticals PLC- in a research note on Monday, March 18th. Two research analysts have rated the stock with a hold rating, ten have given a buy rating and two have issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $180.73.

In related news, insider Volker Knappertz sold 4,140 shares of GW Pharmaceuticals PLC- stock in a transaction on Tuesday, February 26th. The shares were sold at an average price of $12.46, for a total value of $51,584.40. Following the completion of the sale, the insider now owns 9,612 shares in the company, valued at $119,765.52. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Justin D. Gover sold 22,620 shares of GW Pharmaceuticals PLC- stock in a transaction on Wednesday, February 13th. The stock was sold at an average price of $12.50, for a total transaction of $282,750.00. Following the completion of the sale, the chief executive officer now owns 370,445 shares of the company’s stock, valued at approximately $4,630,562.50. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 1,895,496 shares of company stock worth $27,538,565. 5.50% of the stock is currently owned by corporate insiders.

COPYRIGHT VIOLATION WARNING: “Millennium Management LLC Invests $15.69 Million in GW Pharmaceuticals PLC- (NASDAQ:GWPH)” was first published by Modern Readers and is owned by of Modern Readers. If you are reading this piece on another domain, it was illegally copied and republished in violation of international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.modernreaders.com/news/2019/04/11/millennium-management-llc-invests-15-69-million-in-gw-pharmaceuticals-plc-gwph-stock.html.

GW Pharmaceuticals PLC- Profile

GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.

Further Reading: What are the advantages of the Stochastic Momentum Index?

Institutional Ownership by Quarter for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Accuray Incorporated (ARAY) Stock Outlook: The Week That’s Testing Investors

Similar statistics are true for the second largest owner, Renaissance Technologies Llc, which owns 5,507,123 shares of the stock are valued at $25.06 …

Accuray Incorporated (NASDAQ:ARAY) went up to recover about 39.02% since recording its record low price of $3.16. The stock experienced -3.3% slump, arriving at $4.4 on 4/10/2019. During the day, the stock price traveled from $4.37 to $4.56. This company shares are 59.09% off its target price of $7 and the current market capitalization stands at $393.54M. The recent change has given its price a -8.23% deficit over SMA 50 and -18.52% deficit over its 52-week high. The stock witnessed -4.97% declines, 17.65% gains and 6.28% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found ARAY’s volatility during a week at 3.87% and during a month it has been found around 4.34%.

Accuray Incorporated (ARAY) Top Holders

Institutional investors currently hold around $328 million or 84.4% in ARAY stock. Look at its top three institutional owners: Blackrock Inc. owns $37.73 million in Accuray Incorporated, which represents roughly 9.59% of the company’s market cap and approximately 11.5% of the institutional ownership. Similar statistics are true for the second largest owner, Renaissance Technologies Llc, which owns 5,507,123 shares of the stock are valued at $25.06 million. The third largest holder is Primecap Management Co/Ca/, which currently holds $21.54 million worth of this stock and that ownership represents nearly 5.47% of its market capitalization.

Accuray Incorporated 13F Filings

At the end of December reporting period, 81 institutional holders increased their position in Accuray Incorporated (NASDAQ:ARAY) by some 8,557,167 shares, 52 decreased positions by 12,241,042 and 19 held positions by 51,281,423. That puts total institutional holdings at 72,079,632 shares, according to SEC filings. The stock grabbed 29 new institutional investments totaling 2,817,052 shares while 15 institutional investors sold out their entire positions totaling 619,993 shares.

Accuray Incorporated (NASDAQ:ARAY) Insider Trades

Multiple company employees have indulged in significant insider trading. Accuray Incorporated disclosed in a document filed with the US Securities and Exchange Commission (SEC) that President & CEO LEVINE JOSHUA has sold 6,604 shares of Accuray Incorporated (ARAY) in the trading session dated Apr. 02, 2019. These shares are worth $29,982 and were traded at $4.54 each. The SEC filing shows that LEVINE JOSHUA performed a sale of 15,839 shares. The President & CEO disposed these shares by way of transaction on Dec. 03, 2018. The company’s shares were given away at $4 per share worth to an income of some $63,356 to the account of LEVINE JOSHUA.

SVP, COO, Kirkpatrick Andrew J, sold 1,784 common shares of Accuray Incorporated (ARAY) in the open market. In a transaction dated Dec. 03, 2018, the shares were put up for sale at an average price of $4.11, raking in a sum of $7,332. After this sale, 238,136 common shares of ARAY are directly owned by the insider, with total stake valued at $1,047,798.

In the transaction dated Dec. 03, 2018, a great number of shares sold came courtesy the SVP and General Counsel; Chew Jesse disposed a total of 560 shares at an average price of $4.11, amounting to approximately $2,302. The insider now directly owns 36,440 shares worth $160,336.

Accuray Incorporated (ARAY) Analyst Guide

Several analysts have released their opinion on Accuray Incorporated (NASDAQ:ARAY), with 1 analysts believing it is a strong buy. Whereas 3 of them predict the stock is a hold. Also, there are 2 buy, 1 sell and 0 strong sell ratings, collectively assigning a 2.57 average brokerage recommendation [T1].

Related Posts:

  • No Related Posts